Laurus Labs

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

The stock hit a new high of ₹1,095, appreciated 117% from its 52-week low of ₹504.30 touched on January 28, 2025.

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

BSE, Hitachi Energy, GE Vernova, Syrma SGS, Force Motors, HBL Engineering and Laurus Labs have gained more than 50% each after these companies reported over 50% growth in profit in Q1 and Q2 of FY26.

Among the companies trading ex-dividend on Friday, Coforge has declared an interim dividend of ₹4 per share, with the record date set for the same day

HDFC Bank (HDFCB) reported a steady Q2FY26, with profit rising 11 per cent Y-o-Y to ₹186.4 billion, aided by healthy NII of ₹315.5 billion and strong treasury gains of ₹23.9 billion

Thus far in the month of October 2025, Laurus Labs has outperformed the market by surging 14 per cent.

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Q2FY26 company results: Many firms including PTC India Financial Services, Tata Teleservices, Jumbo Bag and Vardhman Textiles are also to release their July-September quarter earnings reports today

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows

Thus far in September, the stock price of Laurus Labs has rallied 6 per cent, as compared to a 1.5 per cent rise in the BSE Sensex and BSE Healthcare index

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Laurus stock price outlook: Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect sustained margin expansion.

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Scale-up of the CDMO segment in FY26, is expected to contribute meaningfully to revenue growth and margin expansion, aided by better capacity utilisation and operational execution, CareEdge Ratings.

Laurus Labs management sees a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation.

Stocks to buy: Analyst at Angel One recommends Ashok Leyland, Grasim and one other stock; Check target price, stop loss here